These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 36448274)

  • 1. Efficacy and safety of BT595 (10% human intravenous immunoglobulin) in adult patients with chronic immune thrombocytopenia.
    Demeter J; Hamed A; László S; Suvajdzic N; Aigner S; Börner B; Staiger C
    Transfus Med; 2023 Apr; 33(2):165-173. PubMed ID: 36448274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of a New 10% Intravenous Immunoglobulin Product in Patients with Primary Immune Thrombocytopenia (ITP).
    Hong J; Bang SM; Mun YC; Yhim HY; Lee J; Lim HS; Oh D;
    J Korean Med Sci; 2018 May; 33(19):e142. PubMed ID: 29736158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of Gammaplex® in idiopathic thrombocytopenic purpura (ClinicalTrials.gov--NCT00504075).
    Dash CH; Gillanders KR; Stratford Bobbitt ME; Gascoigne EW; Leach SJ
    PLoS One; 2014; 9(6):e96600. PubMed ID: 24892422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of a new intravenous immunoglobulin (Panzyga
    Arbach O; Taumberger AB; Wietek S; Cervinek L; Salama A
    Transfus Med; 2019 Feb; 29(1):48-54. PubMed ID: 30687970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of a new intravenous immunoglobulin 10% formulation (octagam® 10%) in patients with immune thrombocytopenia.
    Robak T; Mainau C; Pyringer B; Chojnowski K; Warzocha K; Dmoszynska A; Straub J; Imbach P
    Hematology; 2010 Oct; 15(5):351-9. PubMed ID: 20863431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety and pharmacokinetics of a new 10% normal human immunoglobulin for intravenous infusion, BT595, in children and adults with primary immunodeficiency disease.
    Kriván G; Borte M; Harris JB; Lumry WR; Aigner S; Lentze S; Staiger C
    Vox Sang; 2022 Oct; 117(10):1153-1162. PubMed ID: 35944615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura.
    El Alfy MS; Mokhtar GM; El-Laboudy MA; Khalifa AS
    Acta Haematol; 2006; 115(1-2):46-52. PubMed ID: 16424649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of IQYMUNE®, a Ten Percent Intravenous Immunoglobulin in Adult Patients With Chronic, Primary Immune Thrombocytopenia.
    Rodeghiero F; Woszczyk D; Slama B; Melikyan A; Viallard JF; Ouaja R; Cisse OA; Sadoun A; Salama A
    J Hematol; 2018 Sep; 7(3):87-95. PubMed ID: 32300420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different dosages of intravenous immunoglobulin (IVIg) in treating immune thrombocytopenia with long-term follow-up of three years: Results of a prospective study including 167 cases.
    Zhou Z; Qiao Z; Li H; Luo N; Zhang X; Xue F; Yang R
    Autoimmunity; 2016; 49(1):50-7. PubMed ID: 26525513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy and safety of Flebogammadif, a new high-purity human intravenous immunoglobulin, in adult patients with chronic idiopathic thrombocytopenic purpura.
    Julia A; Kovaleva L; Loria S; Alberca I; Hernandez F; Sandoval V; Sierra J; Vidaller A; Ayguasanosa J; Carretero M
    Transfus Med; 2009 Oct; 19(5):260-8. PubMed ID: 19747289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of intravenous immunoglobulin (Flebogamma
    Apte S; Navarro-Puerto J; Damodar S; Ramanan V; John J; Kato G; Ross C; Shah C; Torres M; Fu C'; Rucker K; Pinciaro P; Barrera G; Aragonés ME; Ayguasanosa J
    Immunotherapy; 2019 Feb; 11(2):81-89. PubMed ID: 30499734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose versus high-dose immunoglobulin for primary treatment of acute immune thrombocytopenic purpura in children: results of a prospective, randomized single-center trial.
    Benesch M; Kerbl R; Lackner H; Berghold A; Schwinger W; Triebl-Roth K; Urban C
    J Pediatr Hematol Oncol; 2003 Oct; 25(10):797-800. PubMed ID: 14528103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy and safety of a novel intravenous immunoglobulin preparation in adult chronic ITP.
    Colovic M; Dimitrijevic M; Sonnenburg C; Suvajdzic N; Donfrid M; Bogdanovic A
    Hematol J; 2003; 4(5):358-62. PubMed ID: 14502262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BT595, a 10% Human Normal Immunoglobulin, for Replacement Therapy of Primary Immunodeficiency Disease: Results of a Subcohort Analysis in Children.
    Kriván G; Borte M; Soler-Palacin P; Church JA; Csurke I; Harris JB; Lieberman JA; Melamed IR; Moy JN; Simon R; Aigner S; Lentze S; Staiger C
    J Clin Immunol; 2023 Apr; 43(3):557-567. PubMed ID: 36383294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of different dose intravenous immunoglobulin in treating acute idiopathic thrombocytopenic purpura: a meta-analysis of 13 randomized controlled trials.
    Qin YH; Zhou TB; Su LN; Lei FY; Zhao YJ; Huang WF
    Blood Coagul Fibrinolysis; 2010 Dec; 21(8):713-21. PubMed ID: 20962624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peri-Operative Eltrombopag or Immune Globulin for Patients with Immune Thrombocytopaenia (The Bridging ITP Trial): Methods and Rationale.
    Arnold DM; Jamula E; Heddle NM; Cook RJ; Hsia C; Sholzberg M; Lin Y; Kassis J; Blostein M; Larratt L; Amini S; Schipperus M; Carruthers J; Lane SJ; Li N; Kelton JG
    Thromb Haemost; 2019 Mar; 119(3):500-507. PubMed ID: 30685874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of idiopathic thrombocytopenic purpura in adults: efficacy of domestic intravenous immunoglobulin in immune thrombocytopenia].
    Pugina SA; Evdokimova NM; Rastorguev GG; Samoĭlova OS; Sorokina IV; Sidnev GV; Vasil'ev DM; Anastasiev VV; Milovidova OV; Molodovskaia EV; Borovkov NN
    Ter Arkh; 1999; 71(8):50-4. PubMed ID: 10515038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The experience of Flebogammadif® in primary immune thrombocytopenia.
    Julia A
    Clin Exp Immunol; 2011 Jun; 164 Suppl 2(Suppl 2):12-5. PubMed ID: 21466547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized study of IVIg and high-dose dexamethasone therapy for children with chronic idiopathic thrombocytopenic purpura.
    Hedlund-Treutiger I; Henter JI; Elinder G
    J Pediatr Hematol Oncol; 2003 Feb; 25(2):139-44. PubMed ID: 12571466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of Privigen, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura.
    Robak T; Salama A; Kovaleva L; Vyhovska Y; Davies SV; Mazzucconi MG; Zenker O; Kiessling P;
    Hematology; 2009 Aug; 14(4):227-36. PubMed ID: 19635187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.